One Year Results for Suprachoroidal Triamcinolone Acetonide Injection in Various Retinal Diseases
Overview
- Phase
- Not Applicable
- Intervention
- Suprachoroidal triamcinolone acetonide injection
- Conditions
- Diabetic Macular Edema
- Sponsor
- Benha University
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Visual acuity
- Last Updated
- 3 years ago
Overview
Brief Summary
Suprachoroidal drug delivery is a recent route for managing various ocular conditions. Safety and long term results are still under investigations.
Detailed Description
In this study, we aim to analyze the long term results of suprachoroidal injection in treating various retinal diseases to focus on its efficacy, safety and long term ocular effects as ocular hypertension, cataract progression and macular edema resolution.
Investigators
Ahmed Abdelshafy
Lecturer of Ophthalmology
Benha University
Eligibility Criteria
Inclusion Criteria
- •cases with central macular thickness more than 250 microns measured by optical coherence tomography due to one of the following conditions:
- •Diabetic macular edema
- •Vogt-koyanagi Harada disease
- •Retinal vein occlusion.
Exclusion Criteria
- •other causes of increased macular thickness as age related macular degeneration and myopic choroidal new vascularization.
- •Cases with confirmed diagnosis of glaucoma.
Arms & Interventions
Diabetic macular edema
Cases with diabetic macular edema with central macular thickness more than 300 microns measured by optical coherence tomography.
Intervention: Suprachoroidal triamcinolone acetonide injection
Vogt-koyanagi harada
Cases with vogt-koyanagi harada and complicated with exudative retinal detachment confirmed by optical coherence tomography.
Intervention: Suprachoroidal triamcinolone acetonide injection
Retinal vein occlusion
Cases with retinal vein occlusion and complicated with macular edema confirmed by optical coherence tomography.
Intervention: Suprachoroidal triamcinolone acetonide injection
Outcomes
Primary Outcomes
Visual acuity
Time Frame: Baseline and up to one year after injection.
Changes noted in vision after injection measured 8n logMar units by snellen chart.
Secondary Outcomes
- Central macular thickness(Baseline and up to one year after injection.)